---
title: "Quanterix Corporation (QTRX.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/QTRX.US/overview.md"
symbol: "QTRX.US"
name: "Quanterix Corporation"
parent: "https://longbridge.com/en/quote/QTRX.US.md"
datetime: "2026-04-05T03:53:18.736Z"
locales:
  - [en](https://longbridge.com/en/quote/QTRX.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/QTRX.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/QTRX.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/QTRX.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/QTRX.US/overview.md)


# Quanterix Corporation (QTRX.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Address | Building 1, 900 Middlesex Turnpike, Billerica, Massachusetts, United States |
| Website | [www.quanterix.com](https://www.quanterix.com) |

## Company Profile

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company’s products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies.

## Key Executives

| Name | Title |
|------|-------|
| William P. Donnelly | Executive Chair |
| David R. Walt | Co-Founder & Chairman of Scientific Advisory Board |
| Vandana Sriram | CFO & Treasurer |
| Everett V. Cunningham | President, CEO & Director |
| Michael Miller | Chief Operating Officer |
| Karen A. Flynn | Independent Director |
| Jeffrey T. Elliott | Lead Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Columbia Management Investment Advisers, LLC | 10.64% | 2025-12-31 |
| Portolan Capital Management, LLC | 9.64% | 2025-12-31 |
| BlackRock, Inc. | 7.19% | 2025-12-31 |
| The Vanguard Group, Inc. | 5.70% | 2025-12-31 |
| Telegraph Hill Partners | 5.34% | 2025-09-30 |
| Blue Water Life Science Advisors, LP | 4.46% | 2025-12-31 |
| William Blair Investment Management, LLC | 4.36% | 2025-12-31 |
| David R. Walt | 3.99% | 2026-01-02 |
| Invenomic Capital Management LP | 3.21% | 2025-12-31 |
| Geode Capital Management, LLC | 2.29% | 2025-12-31 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Diagnostic Kits / Equipment | 138897000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Quanterix Corporation Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Diagnostic Kits / Equipment",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| North America | 85114000 | 61.39% |
| Europe, Middle East, and Africa (EMEA) | 36716000 | 26.48% |
| Asia Pacific | 16824000 | 12.13% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**